GLP-1 수용체 작동제 시장 전망 : 기회, 성장 촉진요인, 산업 동향 분석(2024-2032년)

The Global GLP-1 Receptor Agonist Market reached USD 24.4 billion in 2023 and is projected to grow at a CAGR of 9.7% from 2024 to 2032. This growth is primarily driven by the increasing prevalence of type 2 diabetes and obesity worldwide. According to recent research, the number of individuals living with diabetes is expected to more than double in the coming decades, highlighting the urgent need for effective treatment options.

GLP-1 receptor agonists have gained significant traction due to their dual efficacy in managing type 2 diabetes and promoting weight loss. These drugs mimic natural incretin hormones to regulate blood sugar levels while aiding in weight management, addressing two critical health challenges. As healthcare providers and patients seek effective therapies with minimal side effects, the demand for GLP-1 receptor agonists is expected to rise sharply. Advancements in drug formulations and the proven benefits of these treatments are further fueling market expansion.

By route of administration, the market is segmented into parenteral and oral categories. The parenteral segment, dominated by injectable formulations, accounted for the largest market share in 2023 and is anticipated to maintain its lead through 2032. Injectable GLP-1 receptor agonists are favored for their superior bioavailability and consistent efficacy, making them a reliable choice for managing diabetes and obesity. Although oral alternatives are emerging, injectables dominate due to their well-established clinical success and stable dosing capabilities.

The market is further divided by application into type 2 diabetes, obesity, and other uses. The type 2 diabetes segment held the largest share in 2023 and is expected to experience robust growth. As one of the most widespread chronic diseases globally, type 2 diabetes drives a significant need for efficient management solutions. GLP-1 receptor agonists provide an innovative approach by offering glycemic control weight management benefits, addressing a critical need in diabetes care.

North America GLP-1 receptor agonist market is set to grow substantially through 2032. High diabetes and obesity rates, combined with a strong healthcare infrastructure, contribute to the region's dominance. The United States stands out due to its advanced healthcare ecosystem, significant pharmaceutical investments, and access to innovative treatments. These factors position North America as a key driver of the global GLP-1 receptor agonist market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases such as diabetes and obesity
    • 3.2.1.2 Increasing R&D activities for developing novel therapeutics
    • 3.2.1.3 Formulation advancements of oral GLP-1 receptor agonists
    • 3.2.1.4 Increasing awareness about diagnosis and treatment options for diabetes
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects associated with few GLP-1 agonist drugs
    • 3.2.2.2 Product recalls by market players
• 3.3 Growth potential analysis
  • 3.3.1 By drug class
  • 3.3.2 By route of administration
  • 3.3.3 By application
  • 3.3.4 By distribution channel
• 3.4 Clinical trial analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Global company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class (USD Million)

• 5.1 Key trends
• 5.2 Semaglutide
• 5.3 Dulaglutide
• 5.4 Liraglutide
• 5.5 Exenatide
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration (USD Million)

• 6.1 Key trends
• 6.2 Parenteral
• 6.3 Oral

Chapter 7 Market Estimates and Forecast, By Application (USD Million)

• 7.1 Key trends
• 7.2 Type 2 diabetes mellitus
• 7.3 Obesity
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel (USD Million)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region (USD Million)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Switzerland
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Eli Lilly and Company
• 10.2 Sanofi
• 10.3 Novo-Nordisk A/S
• 10.4 AstraZeneca
• 10.5 Pfizer, Inc.
• 10.6 Amgen, Inc.
• 10.7 Innovent Biologics, Inc.
• 10.8 PegBio Co., Ltd.
• 10.9 Sun Pharmaceutical Industries Ltd.
• 10.10 Boehringer Ingelheim International GmbH